8-K: Fate Therapeutics Reports Positive Data on FT819 and FT825 Programs, Ends Year with $307 Million in Cash

Fate Therapeutics announces promising clinical updates for its FT819 and FT825 cell therapy programs, along with a solid cash position to extend operations through 2026.

Summary

• Fate Therapeutics reported its fourth quarter and full year 2024 financial results and provided business updates on March 5, 2025.
• The company's cash, cash equivalents, and investments totaled $306.7 million as of December 31, 2024, which is projected to fund operations through the end of 2026.
• Revenue for the fourth quarter of 2024 was $1.9 million, derived from preclinical development activities under the collaboration with Ono Pharmaceutical.
• Total operating expenses for the fourth quarter were $63.6 million, including R&D expenses of $33.6 million.
• The company initiated a Phase 1 dose expansion for FT819 in SLE patients using a fludarabine-free conditioning regimen.
• The FDA agreed to allow the clinical investigation of additional B cell-mediated autoimmune diseases under the current Phase 1 clinical trial of FT819.
• The first patient was treated with FT819 as an add-on to maintenance therapy without conditioning chemotherapy in SLE.
• The company is advancing FT825 into higher-dose cohorts as monotherapy and in combination with monoclonal antibody therapy under the Ono collaboration.
• Initial translational data of FT522 without conditioning chemotherapy was presented at ACR Convergence.
• As of December 31, 2024, there were 113.9 million common shares outstanding, 3.9 million pre-funded warrants outstanding, and 2.8 million preferred shares outstanding.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with promising clinical data and a strong cash position. However, the net loss and operating expenses temper the enthusiasm.

Positives

• Strong cash position of $306.7 million provides a runway through YE26.
• Positive clinical data from FT819 Phase 1 trial in SLE, including DORIS clinical remission in the first evaluable patient.
• FDA agreement to expand FT819 trial to include additional autoimmune diseases and a multi-dose treatment cycle.
• Advancement of FT825 into higher-dose cohorts and combination therapy.
• Favorable safety profile observed in initial FT825 clinical data.
• Initial translational data of FT522 without conditioning chemotherapy presented at ACR Convergence.

Negatives

• Total operating expenses were $63.6 million for the fourth quarter of 2024, including research and development expenses of $33.6 million and general and administrative expenses of $15.3 million.
• The company reported a net loss of $52.153 million for the fourth quarter of 2024.
• The company reported a one-time non-cash asset impairment charge of $14.7 million related to equipment and right-of-use assets.

Risks

• The company's research and development programs and product candidates may not demonstrate the requisite safety, efficacy, or other attributes to warrant further development or to achieve regulatory approval.
• Results observed in prior studies of the company's product candidates may not be observed in ongoing or future studies involving these product candidates.
• There is a risk of a delay or difficulties in the manufacturing of the company's product candidates or in the initiation and conduct of, or enrollment of patients in, any clinical trials.
• The company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons.
• Its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects.
• The company may not comply with its obligations under and otherwise maintain its collaboration agreement with Ono.
• Research funding and milestone payments received by the company under its collaboration or from CIRM may be less than expected.
• The company may incur operating expenses in amounts greater than anticipated.

Future Outlook

Fate Therapeutics plans to advance its lead clinical programs in autoimmunity and oncology, provide clinical and regulatory updates on FT819 in SLE, explore FT819 clinical trial expansion in additional autoimmune diseases, and share clinical data from FT825 throughout the year. The company also intends to assess any further clinical development of FT522 in relapsed / refractory BCL upon completion of dose escalation at the second dose level of 900 million cells.

Management Comments

• We begin 2025 with resolve and focus to advance our lead clinical programs in autoimmunity and oncology, said Bob Valamehr, Ph.D. MBA, President and Chief Executive Officer of Fate Therapeutics.
• The team continues to make great progress in our pursuit of achieving therapeutic differentiation for patients with B cell-mediated autoimmune diseases, and we look forward to providing clinical and regulatory updates as we advance our FT819 off-the-shelf CAR T-cell product candidate in SLE.
• We remain focused on driving patient enrollment and engaging with the FDA to further discuss novel development pathways for CAR T-cell therapy in autoimmune disease, including the use of fludarabine-free conditioning as well as add-on to maintenance therapy without conditioning.

Industry Context

Fate Therapeutics is part of a growing field of companies developing iPSC-derived cell therapies. The company's focus on off-the-shelf products aims to overcome limitations associated with patientand donor-sourced cell therapies, potentially offering a more scalable and accessible approach to treating cancer and autoimmune diseases.

Comparison to Industry Standards

• Fate's approach to iPSC-derived cell therapies is comparable to that of companies like Century Therapeutics and Sana Biotechnology, which are also developing allogeneic cell therapies.
• The $306.7 million cash position provides Fate with a competitive advantage, allowing it to fund its clinical programs through 2026, similar to the runway that other well-funded biotech companies possess.
• The clinical data presented on FT819 in SLE is encouraging, particularly the DORIS remission achieved in one patient, which could position Fate favorably against other companies developing CAR T-cell therapies for autoimmune diseases, such as Cabaletta Bio and Kyverna Therapeutics.

Stakeholder Impact

• Shareholders: The positive clinical data and strong cash position are likely to be viewed favorably by shareholders.
• Employees: The company's progress and financial stability provide job security and opportunities for advancement.
• Patients: The development of novel cell therapies offers hope for improved treatment options for cancer and autoimmune diseases.
• Partners: The collaboration with Ono Pharmaceutical is strengthened by the advancement of FT825.

Next Steps

• Initiate dose-expansion cohorts in one or more of AAV, IIM, and SSc in 2025.
• Advance FT825 into higher-dose cohorts as monotherapy and in combination with monoclonal antibody therapy.
• Assess any further clinical development of FT522 in relapsed / refractory BCL upon completion of dose escalation at the second dose level of 900 million cells.
• Provide clinical and regulatory updates on FT819 in SLE.

Key Dates